Home › RetroSense Therapeutics Granted Orphan Drug Designation For Lead Product RST-001 For Retinitis Pigmentosa
 

Keywords :   


RetroSense Therapeutics Granted Orphan Drug Designation For Lead Product RST-001 For Retinitis Pigmentosa

2014-11-05 05:53:53| drugdiscoveryonline Home Page

RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced recently that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP)

Tags: product lead drug granted

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Ryanair profits surge after fares climb by 20%
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
20.05Vantiva RDK device shipments exceed 125 million
20.05VinFast first with Sony Pictures in-car service
20.05LG Ad Solutions to adopt Unified ID 2.0
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
More »